Form D · Other
Curoverse, Inc.
Boston, MA · CIK 0001586571
Offering snapshot reported Mar 25, 2015 · SEC filing
- Reported sold
- $500K Offering amount: $2M
- Investors reported
- 3 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Mar 9, 2015 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Mar 25, 2015 | Initial | $500,000 | No comparison | 3 | SEC filing |
| Feb 19, 2014 | Amendment | $1,699,999 | $200,000vs Sep 12, 2013 | 15 | SEC filing |
| Sep 12, 2013 | Initial | $1,499,999 | No comparison | 15 | SEC filing |
Offering details
- Securities
- Debt
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-236561
Source: Form D, filed Mar 25, 2015. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Jeremy Allaire | Director |
| Adam Berrey | Director, Executive |
| Michael Dial | Director |
| David Martirano | Director |
| Clay Throp | Director |
| Ward Vandewege | Executive |
| Alexander Wait Zaranek | Director |
Issuer details
Industry: Other (See others in industry)
Address:
332 Congress Street 4 Th Floor
Boston, MA, 02210
Boston, MA, 02210